acute myeloid leuxemia

The European Commission has granted full marketing authorization to Bristol Myers Squibb & Co's (NYSE: BMY) Onureg (azacitidine tablets) The approval comes as maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission or...

Actinium Pharmaceuticals Inc (NYSE: ATNM) highlighted data from its pivotal Phase 3 SIERRA trial evaluating Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (AML) aged 55 years and above. Iomab-B radiotherapy is intended to be a targeted conditioning (preparing...

Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting cusatuzumab. The pair first came together to develop the med across various blood cancers and disorders in December...

Forma Therapeutics Holdings Inc (NASDAQ: FMTX) announced interim data from its Phase 2 trial of olutasidenib in relapsed/refractory acute myeloid leukemia (R/R AML). The data will be presented at the upcoming 2021 American Society of Clinical Oncology Annual Meeting. Olutasidenib...

Slingshot Insights, a crowdfunded expert network that offers investment research tools, conducted an expert call on Moleculin Biotech Inc (NASDAQ: MBRX) AML drug Annamycin last Friday. The goal of the call was to offer investors the opportunity to better understand how the drug differs from...